Experimental HIV Vaccine Shows Promise in Early Human Trials

New candidate induces rare broadly neutralizing antibodies, but safety concerns prompt reformulation

The vaccine triggered broadly neutralizing antibodies in a small number of participants after two doses.
Researchers targeted a stable region of the HIV-1 outer envelope to combat various virus strains.
One participant experienced a non-life-threatening allergic reaction, leading to a pause and reformulation of the vaccine.
The trial demonstrated a 95% serum response rate and a 100% blood CD4+ T-cell response rate after two doses.
Further development aims to induce more potent antibodies and target additional sites on the HIV envelope.